| NCT01338883 | Tobira Therapeutics, Inc. | HIV-1 Infection | 2011-06 | PHASE2 |
| NCT00810303 | University Medicine Greifswald | Pharmacokinetics|Drug Interactions|Pharmacodynamics|Intestinal Transporter Expression | 2009-03 | PHASE1 |
| NCT00158821 | Gilead Sciences | HIV Infections | 2000-03 | PHASE3 |
| NCT03706885 | Case Western Reserve University|University Hospitals Cleveland Medical Center|Massachusetts General Hospital | Alzheimer Disease, Early Onset | 2018-05-05 | PHASE1 |
| NCT00615810 | Gilead Sciences | HIV Infections | 2008-03 | PHASE4 |
| NCT00121017 | Abbott | HIV Infection|Hepatitis C | | PHASE2 |
| NCT02631473 | St Stephens Aids Trust|University of Liverpool | HIV | 2015-11 | PHASE1 |
| NCT00000939 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT00365612 | Gilead Sciences|Bristol-Myers Squibb | HIV Infections | 2006-07 | PHASE4 |
| NCT00964002 | Institut Bergonié | Prostate Cancer | 2008-05 | PHASE2 |
| NCT04463784 | Peking Union Medical College Hospital | HIV+AIDS|Mental Impairment | 2018-04-01 | NA |
| NCT00196599 | French National Agency for Research on AIDS and Viral Hepatitis|Triangle Pharmaceuticals|Gilead Sciences|Bristol-Myers Squibb|Dupont Applied Biosciences | HIV Infections|Antiretroviral Naive | 1999-02 | PHASE2 |
| NCT00556634 | Sociedad Andaluza de Enfermedades Infecciosas|Junta de Andalucia | HIV-1 Infection|HIV Infection | 2006-04 | PHASE4 |
| NCT00002362 | Triangle Pharmaceuticals | HIV Infections | 1999-08 | PHASE3 |
| NCT01588002 | Hoffmann-La Roche | Healthy Volunteer | 2012-04 | PHASE1 |
| NCT01878890 | Institut Bergonié | Solid Tumors|Non-Hodgkin´s Lymphoma | 2011-09-05 | PHASE1 |
| NCT00903682 | Janssen-Cilag International NV | HIV Infection|HIV|Acquired Immunodeficiency Syndrome | 2009-06 | PHASE2 |
| NCT01271894 | Kirby Institute|Chelsea and Westminster NHS Foundation Trust | HIV Infection | 2011-09 | PHASE3 |
| NCT00042289 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2003-06-09 | |
| NCT07570069 | Vertex Pharmaceuticals Incorporated | Pain | 2026-05-07 | PHASE1 |
| NCT00162097 | Bristol-Myers Squibb | HIV Infections|Hepatic Impairment | 2004-11 | PHASE1 |
| NCT00002225 | Dupont Merck | HIV Infections | | PHASE2 |
| NCT00002448 | Hoffmann-La Roche | HIV Infections | 1999-10 | PHASE3 |
| NCT00112047 | Gilead Sciences | HIV Infections | 2003-07 | PHASE3 |
| NCT00162643 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|National Council of Science and Technology, Mexico|Instituto Mexicano del Seguro Social | Acquired Immunodeficiency Syndrome | 2004-12 | PHASE4 |
| NCT02269462 | Adeniyi Olagunju|University of Liverpool|Obafemi Awolowo University Teaching Hospital | HIV|Pregnancy|Breastfeeding | 2012-12 | |
| NCT00924898 | University of North Carolina, Chapel Hill|Bristol-Myers Squibb|Gilead Sciences | Acute HIV Infection|HIV Infections | 2005-01 | PHASE4 |
| NCT05789173 | Indiana University|National Institute of General Medical Sciences (NIGMS) | Drug-Drug Interaction | 2023-10-06 | EARLY_PHASE1 |
| NCT02421289 | Mahidol University | Cytochrome P-450 CYP2B6|Efavirenz|HIV | 2013-04 | PHASE1 |
| NCT01668147 | Washington University School of Medicine | Drug Effects | 2012-08 | PHASE1|PHASE2 |
| NCT02285374 | St Stephens Aids Trust|ViiV Healthcare | HIV | 2014-11 | PHASE4 |
| NCT00545558 | University of Cincinnati|National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C|HIV Infections | 2006-04 | PHASE1 |
| NCT02404259 | The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|Khon Kaen University | HIV | 2010-06 | NA |
| NCT06823596 | University of Toronto|Ontario HIV Treatment Network|Maple Leaf Research|Unity Health Toronto | Hiv | 2025-01-14 | NA |
| NCT00110305 | Tibotec Pharmaceuticals, Ireland | Human Immunodeficiency Virus Type 1 | 2005-06 | PHASE2 |
| NCT00444379 | University of California, San Francisco|National Institutes of Health (NIH)|Gilead Sciences|Abbott|Merck Sharp & Dohme LLC | Kaposi´s Sarcoma|HIV Infections | 2007-04 | PHASE4 |
| NCT01187862 | University Hospital, Basel, Switzerland | Cytochrome|Pharmacokinetics | 2010-07 | PHASE1 |
| NCT06914869 | X4 Pharmaceuticals | Healthy Participants | 2025-02-18 | PHASE1 |
| NCT02273765 | ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC|Ministry of Health, Brazil | HIV-1 Infection|Tuberculosis | 2015-09-11 | PHASE3 |
| NCT07193875 | Washington University School of Medicine | HIV | 2023-02-09 | PHASE4 |
| NCT00620438 | Makerere University|Health Research Board, Ireland | HIV Infections|Tuberculosis | 2008-02 | PHASE4 |
| NCT00822315 | ANRS, Emerging Infectious Diseases|Gilead Sciences|Merck Sharp & Dohme LLC | HIV Infections|Tuberculosis | 2009-07 | PHASE2 |
| NCT01098526 | ViiV Healthcare|Shionogi|GlaxoSmithKline | Infections, Human Immunodeficiency Virus and Herpesviridae | 2010-03-16 | PHASE1 |
| NCT00661960 | University of California, Davis | HIV Infections|AIDS | 2008-03 | NA |
| NCT05560360 | Jiangsu HengRui Medicine Co., Ltd. | B-cell Tumors | 2022-11-04 | PHASE1 |
| NCT00992069 | National Institute of Allergy and Infectious Diseases (NIAID) | Tuberculosis|HIV | 2009-12 | PHASE1 |
| NCT00792324 | St Stephens Aids Trust | HIV | 2008-06 | PHASE3 |
| NCT00016601 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2001-06 | NA |
| NCT00993031 | University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Malaria|HIV Infections | 2009-12-15 | PHASE3 |
| NCT00000922 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | NA |
| NCT00525239 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | HIV Infections | 2004-03 | NA |
| NCT01980342 | Johns Hopkins University|American College of Obstetricians and Gynecologists|The Campbell Foundation | Drug Interaction | 2014-10 | PHASE4 |
| NCT03309566 | Laboratorio Elea Phoenix S.A. | Healthy | 2016-09-04 | PHASE4 |
| NCT01277627 | Valme University Hospital|Boehringer Ingelheim | HCV Infection.|HCV Viral Load. | 2011-01 | NA |
| NCT00192595 | Kirby Institute|The University of New South Wales|Gilead Sciences | HIV Infection|Hepatitis B Coinfection | 2004-01 | PHASE4 |
| NCT00031070 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT00350272 | Alexion Pharmaceuticals, Inc.|Achillion, a wholly owned subsidiary of Alexion | HIV Infections | 2006-05 | PHASE2 |
| NCT04504045 | University of Southern Denmark | Diabetes Mellitus, Type 2 | 2020-09-01 | PHASE1 |
| NCT00011895 | GlaxoSmithKline | HIV Infections | 2001-02 | PHASE4 |
| NCT00162188 | Bristol-Myers Squibb | HIV Infection | 2001-05 | |
| NCT00307502 | Germans Trias i Pujol Hospital|Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | HIV Infections | 2005-01 | PHASE1 |
| NCT03227653 | Radboud University Medical Center|Kilimanjaro Christian Medical Centre, Tanzania|Kilimanjaro Clinical Research Institute | Efavirenz|Child Behavior|Cognitive Symptom|Medication Adherence|Drug-Related Side Effects and Adverse Reactions | 2017-06-19 | |
| NCT02164812 | Bristol-Myers Squibb | HIV+AIDS | 2014-07 | PHASE1 |
| NCT00005762 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2001-03 | NA |
| NCT00964171 | Institut Bergonié | Pancreatic Cancer | 2008-08 | PHASE2 |
| NCT00862823 | University of Alabama at Birmingham|Bristol-Myers Squibb | Healthy | 2009-02 | PHASE4 |
| NCT00016718 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2001-08 | PHASE1|PHASE2 |
| NCT00000885 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT01293123 | University of California, San Diego|Merck Sharp & Dohme LLC | HIV | 2011-12 | NA |
| NCT00006208 | Triangle Pharmaceuticals | HIV Infections | 2000-08 | PHASE3 |
| NCT00744809 | Tibotec Pharmaceuticals, Ireland | Human Volunteers | 2008-08 | PHASE1 |
| NCT00116116 | Bristol-Myers Squibb | HIV Infections|AIDS | 2002-03 | PHASE4 |
| NCT00118898 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-09 | PHASE3 |
| NCT00074581 | National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network | HIV Infections | 2005-02 | PHASE3 |
| NCT07482085 | Xuanwu Hospital, Beijing | Creutzfeldt-Jakob Disease | 2026-03 | PHASE3 |
| NCT02475915 | SEARCH Research Foundation|Thai Red Cross AIDS Research Centre|Cooper Human Systems | Acute HIV Infection | 2015-01 | PHASE1|PHASE2 |
| NCT00870363 | University of California, Davis | HIV Infections | 2009-04 | PHASE4 |
| NCT00002393 | Dupont Merck | HIV Infections | | PHASE3 |
| NCT00256828 | Clinical Trial Agency of HIV Study Group | HIV Infections | 2004-06 | PHASE4 |
| NCT03405194 | Haitian Group for the Study of Kaposi´s Sarcoma and Opportunistic|Gilead Sciences|Brigham and Women´s Hospital|Weill Medical College of Cornell University|Analysis Group, Inc. | HIV+AIDS | 2018-05-01 | NA |
| NCT01194856 | The Cleveland Clinic|National Institute of Allergy and Infectious Diseases (NIAID)|Case Western Reserve University|Bristol-Myers Squibb | HIV Infection|Mitochondrial Dysfunction | 2010-10 | PHASE4 |
| NCT01087814 | University of Minnesota | HIV|HIV Infections | 2010-02 | PHASE4 |
| NCT00966160 | University of Cologne | Acquired Immunodeficiency Syndrome|HIV Infections | 1999-01 | PHASE3 |
| NCT01516060 | Kirby Institute|The HIV Netherlands Australia Thailand Research Collaboration | HIV | 2012-01 | PHASE3 |
| NCT01410058 | University of Zimbabwe|State University of New York at Buffalo|Biomedical Research and Training Institute | HIV | 2013-01 | |
| NCT00001758 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 1997-11 | PHASE2 |
| NCT01900015 | Juan Macías | HCV Coinfection|HIV Infection | 2014-02-03 | PHASE4 |
| NCT00038532 | Abbott | HIV Infections | 2001-04 | PHASE2 |
| NCT00000912 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT00668395 | Indiana University | HIV | 2007-05 | NA |
| NCT00532168 | Juan A. Arnaiz | HIV Infections | 2007-09 | PHASE4 |
| NCT02935075 | Shanghai Public Health Clinical Center|Yunnan Provincial Infectious Disease Hospital|The Second Hospital of Nanjing Medical University | HIV Infections | 2018-03-05 | PHASE4 |
| NCT00018083 | National Center for Research Resources (NCRR)|Centers for Disease Control and Prevention | Tuberculosis|HIV Infections | | NA |
| NCT01695954 | NYU Langone Health|New York City Health and Hospitals Corporation|Kowa Pharmaceuticals America, Inc.|University at Buffalo | Hyperlipidemia|HIV | 2012-05 | PHASE1 |
| NCT00357188 | Bristol-Myers Squibb | HIV Infections|Protease Inhibitor | 2006-07 | PHASE1 |
| NCT00002220 | Merck Sharp & Dohme LLC | HIV Infections | | PHASE3 |
| NCT00863668 | University of Minnesota|Merck Sharp & Dohme LLC | HIV Infection|HIV Infections | 2009-03 | NA |
| NCT02499874 | St Stephens Aids Trust|Mylan Inc. | HIV | 2015-08 | PHASE1 |
| NCT00000918 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT01541085 | Janssen-Cilag S.p.A. | Human Immunodeficiency Virus; HIV | 2011-12 | |
| NCT02226991 | Boehringer Ingelheim | Healthy | 2006-04 | PHASE1 |
| NCT02832778 | St Stephens Aids Trust|Mylan Inc.|United States Agency for International Development (USAID) | HIV | 2016-11-21 | PHASE1 |
| NCT00100581 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|Hepatitis C | | NA |
| NCT05330273 | Novartis Pharmaceuticals|Medicines for Malaria Venture | Malaria | 2022-04-28 | PHASE1 |
| NCT00002239 | Hoffmann-La Roche|Trimeris | HIV Infections | 1999-05 | PHASE2 |
| NCT03983239 | Celgene|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation | Healthy Volunteers | 2019-06-21 | PHASE1 |
| NCT00433719 | University of Oxford|Wellcome Trust | HIV Infections|Tuberculous Meningitis | 2005-09 | NA |
| NCT03284645 | Obafemi Awolowo University|Federal Medical Centre, Makurdi|University of Liverpool|University of California, San Diego|London School of Hygiene and Tropical Medicine | Human Immunodeficiency Virus Infection | 2017-12-22 | |
| NCT00002419 | Gilead Sciences|Glaxo Wellcome|Dupont Applied Biosciences | HIV Infections | | PHASE2 |
| NCT00944957 | University Hospital, Geneva|University of Bern|University of Lausanne Hospitals|Hospital Lugano|University Hospital, Basel, Switzerland|Hospital of Neuchatel|University Hospital, Zürich | Sleep Disorders|HIV Infections | 2009-11 | NA |
| NCT04513379 | Shanghai Public Health Clinical Center | HIV Infections|Tuberculosis | 2020-11-01 | PHASE3 |
| NCT00483054 | Bamrasnaradura Infectious Diseases Institute|Mahidol University|Chulalongkorn University | HIV Infections|Tuberculosis | 2007-01 | PHASE3 |
| NCT00792584 | University Hospital, Geneva|University of Bern|University of Lausanne Hospitals|Hospital Lugano|University Hospital, Basel, Switzerland|Hospital of Neuchatel | Sleep Disorders | 2008-11 | NA |
| NCT00234091 | National Institute of Allergy and Infectious Diseases (NIAID)|Comprehensive International Program of Research on AIDS | HIV Infections | 2006-04 | PHASE3 |
| NCT01040091 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2009-12 | PHASE1 |
| NCT01641809 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus|HIV Infections | 2012-08-06 | PHASE2 |
| NCT00549198 | GlaxoSmithKline | Infection, Human Immunodeficiency Virus I|HIV Infection | 2007-06 | PHASE4 |
| NCT00017758 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|HIV Seronegativity|Lipodystrophy | | PHASE1 |
| NCT00364793 | Bristol-Myers Squibb | HIV Infections | 2007-02 | PHASE1|PHASE2 |
| NCT00476606 | The HIV Netherlands Australia Thailand Research Collaboration|Khon Kaen University | HIV Infections | 2003-03 | |
| NCT00266058 | University of California, San Francisco | HIV Infections|Malaria | 2005-12 | PHASE1 |
| NCT02489461 | Viriom | HIV-1-infection | 2014-08-05 | PHASE2|PHASE3 |
| NCT00759070 | Juan A. Arnaiz|Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau|Germans Trias i Pujol Hospital|Hospital Universitari Joan XXIII de Tarragona.|Hospitales Universitarios Virgen del Rocío | HIV Infections | 2008-09 | PHASE4 |
| NCT01472380 | Mutual Pharmaceutical Company, Inc. | Healthy | 2011-11 | PHASE1 |
| NCT00001119 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 1999-10 | NA |
| NCT00005018 | Glaxo Wellcome | HIV Infections | 1999-07 | PHASE4 |
| NCT00332306 | Tuberculosis Research Centre, India|National AIDS Control Organisation|Indian Council of Medical Research | Tuberculosis|Human Immunodeficiency Virus Infections | 2006-06 | PHASE3 |
| NCT06698016 | Merck Sharp & Dohme LLC | Healthy | 2023-07-25 | PHASE1 |
| NCT00640887 | French National Agency for Research on AIDS and Viral Hepatitis | HIV Infections|Tuberculosis | 2009-02 | PHASE2 |
| NCT00457665 | University of Texas Southwestern Medical Center|Bristol-Myers Squibb|GlaxoSmithKline | HIV Infections | 2002-02 | PHASE4 |
| NCT00697892 | Fran Aweeka | HIV Infections|Malaria | 2005-07 | PHASE1 |
| NCT00091936 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|Tuberculosis | 2009-08 | NA |
| NCT02945163 | Shanghai Public Health Clinical Center|The Second Hospital of Nanjing Medical University|Yunnan Provincial Infectious Disease Hospital | HIV Infections | 2018-03-05 | PHASE4 |
| NCT00000903 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE3 |
| NCT01011413 | Kirby Institute | HIV Infections | 2011-08 | PHASE3 |
| NCT01989910 | Taipei Veterans General Hospital, Taiwan | HIV-1 Infection | 2013-09 | PHASE4 |
| NCT07565441 | Jemincare|Zhejiang Hangyu Pharmaceutical Co., Ltd. | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | 2026-05-11 | PHASE1 |
| NCT00001086 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT00533390 | Oswaldo Cruz Foundation|Ministry of Health, Brazil | Tuberculosis|HIV Infections | 2007-01 | PHASE4 |
| NCT00120510 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|Tuberculosis | 2007-07 | NA |
| NCT03336346 | Columbia University | Contraceptive Usage|HIV Infections|Drug Interaction | 2017-11-15 | |
| NCT03886766 | University Hospital, Basel, Switzerland|University of Basel | Biological Availability|Amorphous Solid Dispersions | 2019-04-30 | NA |
| NCT00004582 | ViRx | HIV Infections | | PHASE2 |
| NCT00051090 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|Hepatitis B | | NA |
| NCT00075231 | Abbott | HIV Infections | 2003-12 | PHASE2 |
| NCT05909644 | Biogen|Celerion|Q2 Solutions|Altasciences Company Inc. | Healthy Adult Subjects | 2023-07-05 | PHASE1 |
| NCT00158457 | French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba | HIV Infection | 2004-06 | PHASE3 |
| NCT00802802 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections|Tuberculosis | 2010-02-10 | PHASE1 |
| NCT00158470 | French National Agency for Research on AIDS and Viral Hepatitis | HIV Infection | 2003-09 | PHASE3 |
| NCT01231555 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus | 2010-11-18 | PHASE2 |
| NCT00002235 | Merck Sharp & Dohme LLC|Agouron Pharmaceuticals | HIV Infections | | PHASE2 |
| NCT05076682 | Fudan University | Triple-negative Breast Cancer | 2022-06-30 | PHASE2 |
| NCT01789879 | University of Nebraska|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Makerere University|University of Liverpool | HIV|Contraception | 2014-03-04 | PHASE2 |
| NCT00002387 | Merck Sharp & Dohme LLC | HIV Infections | | NA |
| NCT00006190 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | HIV Infections|Lipodystrophy | 2000-11 | PHASE4 |
| NCT00100568 | National Institute of Allergy and Infectious Diseases (NIAID)|Initiative Senegalaise d´Acces aux Antiretroviraux (ISAARV) | HIV Infections | 2006-07 | NA |
| NCT00260078 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2006-02 | PHASE1|PHASE2 |
| NCT00002447 | Hoffmann-La Roche | HIV Infections | 1999-10 | PHASE3 |
| NCT00399685 | Bristol-Myers Squibb | HIV Infections | 2006-12 | PHASE1 |
| NCT00080522 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-02 | NA |
| NCT00038220 | Abbott | HIV Infections | 2000-07 | PHASE2 |
| NCT00255840 | CIPRA SA|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2006-07 | NA |
| NCT00836212 | University Hospital, Geneva|Swiss HIV Cohort Study | Human Immunodeficiency Virus|HIV Infections | 2008-03 | PHASE4 |
| NCT01254656 | Pfizer|ViiV Healthcare | HIV-1 | 2011-02 | PHASE2 |
| NCT00135369 | Bristol-Myers Squibb | HIV Infections | 2002-09 | PHASE3 |
| NCT00075907 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2004-07 | PHASE3 |
| NCT00023413 | Centers for Disease Control and Prevention|US Department of Veterans Affairs | HIV Infections|Tuberculosis | 1999-11 | PHASE2 |
| NCT00730223 | Vanderbilt University | HIV Infections | 2004-03 | PHASE1 |
| NCT00314626 | Germans Trias i Pujol Hospital|Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | HIV Infections | 2004-11 | PHASE3 |
| NCT00299091 | Germans Trias i Pujol Hospital | HIV | 2006-09 | PHASE4 |
| NCT00005017 | Glaxo Wellcome | HIV Infections | | PHASE4 |
| NCT00116298 | Bristol-Myers Squibb | HIV Infections|AIDS | 2001-01 | PHASE3 |
| NCT00005000 | Agouron Pharmaceuticals | HIV Infections | 1999-12 | PHASE4 |
| NCT00050895 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE3 |
| NCT05067439 | Pfizer | Healthy Participants | 2021-10-21 | PHASE1 |
| NCT00386659 | Hospital Clinic of Barcelona | HIV Infection | | PHASE4 |
| NCT01805258 | All India Institute of Medical Sciences|National AIDS Control Organisation | HIV+TB Co-infection | 2007-06 | PHASE3 |
| NCT01104376 | Indiana University|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS) | Efavirenz, Metabolism and Pharmacokinetics Changes | 2010-03 | NA |
| NCT00280969 | International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan | HIV Infection | 2005-09 | PHASE3 |
| NCT00540449 | Tibotec Pharmaceuticals, Ireland | HIV Infections|HIV-1|Human Immunodeficiency Virus Type 1 | 2008-05 | PHASE3 |
| NCT03178084 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | HIV+AIDS | 2014-10-15 | PHASE3 |
| NCT00192660 | Kirby Institute|St Vincent´s Hospital, Sydney|National Heart, Lung, and Blood Institute (NHLBI) | HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease | 2003-02 | PHASE4 |
| NCT01585038 | Indiana University|Janssen Services, LLC | Cardiovascular Disease | 2012-07 | PHASE4 |
| NCT01241773 | Tibotec Pharmaceuticals, Ireland | Hepatitis C Virus | 2010-10 | PHASE1 |
| NCT00100048 | Merck Sharp & Dohme LLC | HIV Infections|Acquired Immunodeficiency Syndrome | 2005-01 | PHASE2 |
| NCT00878306 | University of California, San Francisco|National Institute on Drug Abuse (NIDA) | HIV Infections|Drug Abuse | 2008-11 | PHASE1 |
| NCT00002213 | Glaxo Wellcome | HIV Infections | | PHASE2 |
| NCT00001766 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 1998-08 | PHASE1 |
| NCT01516970 | Janssen-Cilag G.m.b.H | Human Immunodeficiency Virus (HIV) | 2011-11-25 | PHASE3 |
| NCT00158405 | French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb | HIV Infections | 2002-12 | PHASE3 |
| NCT00127972 | International Antiviral Therapy Evaluation Center|Boehringer Ingelheim | HIV Infections | 2004-02 | PHASE4 |
| NCT01632891 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection|Pf Subclinical Parasitemia | 2014-01-10 | PHASE1|PHASE2 |
| NCT00197613 | Harvard School of Public Health (HSPH)|Princess Marina Hospital, Botswana|Botswana Ministry of Health|McGill University Health Centre+Research Institute of the McGill University Health Centre|Bristol-Myers Squibb | AIDS|HIV Infection | 2002-12 | PHASE3 |
| NCT00951015 | ViiV Healthcare|Shionogi|GlaxoSmithKline | Infection, Human Immunodeficiency Virus | 2009-07-30 | PHASE2 |
| NCT00001122 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT00000893 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 1997-10 | PHASE1 |
| NCT00734344 | University of Alabama at Birmingham|Merck Sharp & Dohme LLC | Acute HIV Infection | 2008-09 | NA |
| NCT00135343 | Bristol-Myers Squibb | HIV Infections | 2004-04 | PHASE3 |
| NCT00098293 | ViiV Healthcare|Pfizer | HIV-1 | 2004-11 | PHASE3 |
| NCT00476424 | The HIV Netherlands Australia Thailand Research Collaboration|Ministry of Education, Thailand | HIV Infections | 2007-06 | PHASE2 |
| NCT00084136 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-05 | PHASE4 |
| NCT01935830 | Washington University School of Medicine | Healthy Volunteers | 2013-08 | EARLY_PHASE1 |
| NCT00482963 | University of Colorado, Denver|The Miriam Hospital|University of Washington|Bristol-Myers Squibb | HIV Infections|Contraception|Pharmacokinetics | 2007-05 | PHASE1 |
| NCT00122538 | French National Agency for Research on AIDS and Viral Hepatitis | HIV Infections|AIDS | 2006-02 | PHASE2 |
| NCT01571414 | National Institute of Allergy and Infectious Diseases (NIAID) | Tuberculosis | 2012-05 | PHASE1 |
| NCT01387022 | Centre for the AIDS Programme of Research in South Africa | Antiretroviral Treatment Outcomes | 2011-06 | NA |
| NCT01886404 | University of Nebraska | HIV Infection | 2013-12-01 | |
| NCT00978068 | University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Malaria|HIV Infections | 2009-09 | PHASE3 |
| NCT00442962 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2007-05 | PHASE4 |
| NCT00127959 | International Antiviral Therapy Evaluation Center|Gilead Sciences | HIV Infections|Hepatitis B | 2004-03 | PHASE4 |
| NCT04596488 | Peking Union Medical College Hospital|National Key Technologies R&D Program for the 13th Five-year Plan|National Key Technologies R&D Program for the 12th Five-year Plan|CAMS Initiative for Innovative Medicine | HIV-1-infection | 2017-06-01 | NA |
| NCT05995249 | Takeda | Healthy Volunteers | 2023-08-11 | PHASE1 |
| NCT00543725 | Tibotec Pharmaceuticals, Ireland | HIV Infections|HIV-1 | 2008-06 | PHASE3 |
| NCT02426866 | Bristol-Myers Squibb|Truven health | HIV+AIDS | 2014-12 | |
| NCT00727597 | Georgetown University|GlaxoSmithKline | Human Immunodeficiency Virus Infections | 2008-07 | PHASE3 |
| NCT00028327 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE3 |
| NCT00369941 | Merck Sharp & Dohme LLC | HIV Infections | 2006-08 | PHASE3 |
| NCT00000919 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | NA |
| NCT02777229 | ANRS, Emerging Infectious Diseases|Institut de Recherche pour le Developpement|UNITAID | HIV-1 Infection | 2016-07 | PHASE3 |
| NCT02401256 | Indiana University|National Institute of General Medical Sciences (NIGMS) | Healthy | 2013-07 | PHASE4 |
| NCT01709084 | Janssen-Cilag International NV | Human Immunodeficiency Virus-type 1 Infection | 2013-10-02 | PHASE3 |
| NCT00775606 | Rush University Medical Center|University of Chicago|University of Illinois at Chicago|Ruth M. Rothstein CORE Center|Abbott|Gilead Sciences | Acquired Immune Deficiency Syndrome | 2008-10 | PHASE4 |
| NCT00344760 | University of Maryland, Baltimore | HIV Infections | 2005-01 | PHASE4 |
| NCT00002227 | Dupont Merck | HIV Infections | | PHASE2 |
| NCT00004585 | Glaxo Wellcome | HIV Infections | 1999-10 | PHASE4 |
| NCT00495326 | French National Agency for Research on AIDS and Viral Hepatitis|Medecins Sans Frontieres, Netherlands | Tuberculosis|Aids|Hiv Infections | 2007-12 | PHASE2|PHASE3 |
| NCT01192035 | University of Aarhus|Aarhus University Hospital Skejby|Bandim Health Project|Ministry of Health, Guinea-Bissau|Abbott | HIV-1 | 2011-05 | PHASE4 |
| NCT00053638 | GlaxoSmithKline | HIV Infection | 2003-02 | PHASE3 |
| NCT01445223 | G?teborg University | HIV | 2004-04 | PHASE4 |
| NCT01583439 | Harvard School of Public Health (HSPH)|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2012-09 | NA |
| NCT01451333 | Kirby Institute|Imperial College London | HIV Infection | 2011-09 | PHASE3 |
| NCT00004852 | Glaxo Wellcome | HIV Infections | 1999-09 | PHASE2 |
| NCT00984152 | Rush University Medical Center|Merck Sharp & Dohme LLC | HIV-1 Infections | 2011-06 | PHASE3 |
| NCT04390334 | Idorsia Pharmaceuticals Ltd. | Healthy | 2020-05-13 | PHASE1 |
| NCT00001087 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT00002230 | Northwestern University | HIV Infections | | PHASE3 |
| NCT00000914 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | NA |
| NCT00115609 | French National Agency for Research on AIDS and Viral Hepatitis | HIV Infections|Tuberculosis | 2006-01 | PHASE3 |
| NCT00002234 | Gilead Sciences|Bristol-Myers Squibb|Glaxo Wellcome|Dupont Applied Biosciences | HIV Infections | | PHASE2 |
| NCT03762928 | Pfizer | Healthy Subjects | 2018-12-07 | PHASE1 |
| NCT00196612 | French National Agency for Research on AIDS and Viral Hepatitis|Triangle Pharmaceuticals|Gilead Sciences|Bristol-Myers Squibb|Dupont Applied Biosciences | HIV Infections | 2001-04 | PHASE3 |
| NCT02722421 | University of Nebraska|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Infectious Diseases Institute, Uganda|University of Liverpool|Northwestern University Feinberg School of Medicine | HIV|Contraception | 2017-04-06 | PHASE2 |
| NCT01618305 | Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2013-09-05 | PHASE4 |
| NCT01380080 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 2011-10 | PHASE4 |
| NCT00023218 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|Hepatitis C | | NA |
| NCT01146873 | Columbia University|University of Witwatersrand, South Africa|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV+AIDS|HIV Infections | 2010-07 | PHASE3 |
| NCT01489046 | Bristol-Myers Squibb | HIV-1 Infection | 2011-02 | PHASE2 |
| NCT00960570 | Mutual Pharmaceutical Company, Inc. | Healthy | 2008-02 | PHASE1 |
| NCT02057796 | ANRS, Emerging Infectious Diseases | HIV-1 Infection | 2014-09 | PHASE4 |
| NCT00162227 | Bristol-Myers Squibb | HIV Infection | 2000-09 | |
| NCT06797674 | Merck Sharp & Dohme LLC | Healthy | 2025-02-10 | PHASE1 |
| NCT00013520 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE3 |
| NCT04459598 | Daiichi Sankyo Co., Ltd. | Healthy Subjects|Drug-drug Interaction|Pharmacokinetics|Quizartinib | 2020-08-19 | PHASE1 |
| NCT00014937 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | NA |
| NCT07341672 | Sunshine Lake Pharma Co., Ltd. | Healthy Adult Subject | 2026-12-31 | PHASE1 |
| NCT00523458 | Stanford University | HIV Infections|Tuberculosis | 2007-07 | PHASE4 |
| NCT01632345 | Merck Sharp & Dohme LLC | HIV Infections | 2012-10-12 | PHASE2 |
| NCT00021463 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections|Lipodystrophy | | PHASE2 |
| NCT01014481 | Bamrasnaradura Infectious Diseases Institute|Mahidol University|Thai Red Cross AIDS Research Centre | HIV Infections|Tuberculosis | 2009-10 | PHASE4 |
| NCT02547844 | Hospital Universitari Vall d´Hebron Research Institute|Gilead Sciences | HIV-1 | 2015-09 | PHASE4 |
| NCT01641016 | PENTA Foundation|Medical Research Council|ANRS, Emerging Infectious Diseases | HIV | 2011-04 | PHASE2|PHASE3 |
| NCT00102960 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-07 | PHASE3 |
| NCT00005918 | Bristol-Myers Squibb | HIV Infections | 2000-06 | PHASE3 |
| NCT00224458 | Gilead Sciences | HIV Infections | 2004-09 | PHASE4 |
| NCT00013897 | Bristol-Myers Squibb | HIV Infections | 2001-02 | PHASE3 |
| NCT00342355 | National Institutes of Health Clinical Center (CC) | HIV | 2004-01 | PHASE4 |
| NCT01268839 | Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | HIV | 2010-01 | PHASE1 |
| NCT00006154 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE3 |
| NCT00302822 | French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche|Gilead Sciences | HIV Infections|AIDS | 2006-04 | PHASE3 |
| NCT04680091 | Jiangsu HengRui Medicine Co., Ltd. | Healthy Subjects, Drug-drug Interaction, Pyrotinib | 2020-11-12 | PHASE1 |
| NCT01147107 | University of Hawaii|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Viet Tiep Hospital|Oxford University Clinical Research Unit, Vietnam | Hepatitis C, Chronic|HIV Infection | 2014-02 | PHASE4 |
| NCT00100594 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-05 | NA |
| NCT01075152 | University of Minnesota|Mbarara University of Science and Technology|Makerere University|National Institute of Allergy and Infectious Diseases (NIAID)|University of Cape Town | Cryptococcal Meningitis|HIV Infections|AIDS | 2010-11 | PHASE4 |
| NCT00454337 | French National Agency for Research on AIDS and Viral Hepatitis|Merck Sharp & Dohme LLC | HIV Infections | 2007-05 | PHASE3 |
| NCT01344148 | Shanghai Public Health Clinical Center | AIDS | 2009-02 | NA |
| NCT00427297 | University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2007-09 | PHASE3 |
| NCT03852849 | National Center for AIDS+STD Control and Prevention, China CDC|Yunnan Center for Disease Control and Prevention|Yunnan AIDS Care Center | Viral Suppression of HIV Infection | 2019-03-01 | NA |
| NCT02284035 | Juan A. Arnaiz | AIDS | 2015-09-27 | PHASE3 |
| NCT00824421 | Pfizer | HIV-1 | 2009-02 | PHASE2 |
| NCT02415595 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus | 2015-05-12 | PHASE2 |
| NCT00615745 | Gilead Sciences | HIV Infections | 2008-04 | PHASE4 |
| NCT00978237 | Juan A. Arnaiz | HIV Infections|Lipoatrophy | 2009-10 | PHASE4 |
| NCT02632474 | Shanghai Public Health Clinical Center | HIV Infections | 2015-04 | PHASE4 |
| NCT01565889 | Gilead Sciences | Hepatitis C|HIV | 2012-03 | PHASE1|PHASE2 |
| NCT04109183 | Henan Genuine Biotech Co., Ltd.|Beijing YouAn Hospital|Peking Union Medical College Hospital|Beijing Ditan Hospital|Guangzhou 8th People´s Hospital|The Sixth People´s Hospital of Zhengzhou | AIDS | 2017-10-10 | PHASE2 |
| NCT02178592 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus|HIV Infections | 2015-01-23 | PHASE3 |
| NCT01714414 | Michael Hoelscher|European and Developing Countries Clinical Trials Partnership (EDCTP)|German Federal Ministry of Education and Research|National Institute for Medical Research, Tanzania|Treichville Academic hospital center, Division of infectious and tropical diseases (SMIT)|ANRS, Emerging Infectious Diseases|Kumasi Centre for Collaborative Research (KCCR)|Bernhard Nocht Institute for Tropical Medicine|Pharmaceutical Company (Chiracon GmbH)|Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.) | HIV-1 Infection | 2012-12 | PHASE2 |
| NCT02253823 | Boehringer Ingelheim | Healthy | 2001-12 | PHASE1 |
| NCT04303598 | Henan Genuine Biotech Co., Ltd. | HIV-infection+Aids | 2020-04-01 | PHASE3 |
| NCT01903031 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 2014-12-30 | PHASE2 |